

PROGRAM NORDIC HIV & VIROLOGY CONFERENCE 2022

Wednesday 28 September

10.00	Opening Session Moderators: Leo Flamholz & Magnus Gisslén
10.15-10.20	Welcome - Magnus Gisslén, Sweden
10.20-10.50	Opening Plenary: The path towards HIV cure – Ole Sogaard, Denmark
10.50-11.00	Discussion
11.00	Abstract Session 1 Moderators: Leo Flamholz & Magnus Gisslén
11.00-11.15	Oral 1: Kai J Kauppinen, Finland
11.15-11.30	Oral 2: Malin H. Meyer-Myklestad, Norway
11.30-11.45	Oral 3: Rafael Ceña Diez, Sweden
11.45-12.00	Oral 4: Finn A Filén, Sweden
12.00	Lunch
13.00	Plenary Session I - HIV immunology and vaccines Moderators: Annika Karlsson & Helene Mens
13.00-13.30	Plenary 2: Antiviral T cell responses in tissue and blood "what do they tell us" – Markus Buggert, Sweden
13.30-13.40	Discussion
13.40-14.10	Plenary 3: HIV-prevention by antibodies – Results from the AMP trials – Carolyn Williamson, South Africa
14.10-14.20	Discussion
14.20	Short break
14.40	Plenary Session II - HIV Reservoirs and cure Moderators: Jan Gerstoft & Anders Sönnernborg
14.40-15.10	Plenary 4: New developments in targeting HIV persistence on antiretroviral therapy – Thomas Aagaard Rasmussen, Denmark
15.10-15.20	Discussion
15.20-15.50	Plenary 5: Impact of naïve infection on the HIV-1 reservoir – Una O'Doherty, USA
15.50-16.00	Discussion
16.00	Coffee and exhibition/posters
16.30	Satellite Symposia I - GSK Long-acting agents for HIV in the Nordics: understanding the unmet need – Marta Boffito, United Kingdom, Raquel Martin-Iguacel, Denmark, Jussi Sutinen, Finland, Britt Andersen, Norway, Carl Johan Treutiger, Sweden
17.20	Short break
17.30	Satellite Symposia II - Gilead Long-term treatment success for PLWH; reaching far beyond viral suppression – Felipe Rogatto, United Kingdom Long-term integrated safety/tolerability and efficacy analysis of BIC/FTC/TAF in treatment-naïve adults with HIV through five years of follow-up – Ana Milinkovic, United Kingdom
18.20	Poster Exhibition with cheese and snacks

Thursday 29 September

08.00	Satellite Symposia III - Gilead Hepatitis Delta (HDV) screening, diagnosis and treatment: experience with Hepcludex – Jörg Petersen, Germany
08.50	Short break
09.00	Plenary Session III - HIV antiretroviral treatment Moderators: Jan Gerstoft & Magnús Gottfreðsson
09.00-09.30	Plenary 6: Public health approach to HIV treatment and resistance issues – Nicholas Paton, Singapore
09.30-09.40	Discussion
09.40-10.10	Plenary 7: Injectables and other long acting antivirals – Tristan Barber, United Kingdom
10.10-10.20	Discussion
10.20	Coffee and poster exhibition
10.50	Plenary Session III continues Plenary 8: Monkeypox – John Thornhill, United Kingdom
10.50-11.20	
11.20-11.30	Discussion
11.30	Plenary Session IV - HIV pregnancy and co-morbidities Moderators: Nina Weis & Aylin Yilmaz
11.30-12.00	Plenary 9: HIV & Pregnancy: How far have we come? – Ellen Moseholm, Denmark
12.00-12.10	Discussion
12.10-12.40	Plenary 10: Cardiovascular Disease in Contemporary HIV Care – Lene Ryom, Denmark
12.40-12.50	Discussion
12.50	Lunch
13.50	Plenary Session V - Hepatitis Moderators: Soo Aleman & Henna Rautiainen
13.50-14.20	Plenary 11: New therapeutic strategies for Hepatitis B – Maria Buti, Spain
14.20-14.30	Discussion
14.30-15.00	Plenary 12: Recently approved or new HDV therapies in pipeline – Pietro Lampertico, Italy
15.00-15.10	Discussion
15.10	Plenary Session VI - Last year's most important achievements in the HIV research field Moderators: Christina Carlander & Jussi Sutinen
15.10-15.40	Plenary 13: Top 5 in basic HIV research 2021-2022 – Peter Svensson, Sweden
15.40-16.10	Plenary 14: Top 5 in clinical HIV research 2021-2022 – Piotr Nowak, Sweden
16.10	Coffee and exhibition/posters
16.40	HIV & Virology Conference 2022 Abstract Award Presenter: Arild Maeland, Norway
17.00	Satellite Symposia IV - Pfizer 17.00-17.50 Scientific Breakthroughs to Help Prevent and Treat COVID-19 – Mikael Dolsten, USA/Sweden
19.30	Dinner

Friday 30 September

08.00	Satellite Symposia V - AstraZeneca The Immunocompromised Patient and Pre-Exposure Prophylaxis of Covid-19 Virological Aspects of Pre-Exposure Prophylaxis in Covid-19 – Anders Sönnernborg, Sweden Clinical Trials and Real World Evidence in the PreP setting – Fredrik Månsson, Sweden Panel Discussion – Anders Sönnernborg & Fredrik Månsson, Sweden
08.50	Short break
09.00	Abstract Session II Moderators: Sara Cajander & Aylin Yilmaz 09.00-09.15 Oral 5: Thomas R. Müller, Sweden 09.15-09.30 Oral 6: Christina Sølund, Denmark
09.30	Plenary Session VII - Covid-19 clinical challenges and treatment Moderators: Sara Cajander & Aylin Yilmaz
09.30-10.00	Plenary 15: Covid-19 clinical challenges and treatment from an ICU perspective – Anders Perner, Denmark
10.00-10.10	Discussion
10.10-10.40	Plenary 16: Evidence based treatments during the different phases of COVID-19 – Sara Cajander, Sweden
10.40-10.50	Discussion
10.50	Coffee and Poster exhibition
11.20	Plenary Session VIII - SARS-CoV-2 vaccines incl future perspectives of treatment and vaccination Moderators: Soo Aleman & Leo Flamholz
11.20-11.50	Plenary 17: Perspective on current and future COVID-19 vaccine strategies – Matti Sällberg, Sweden
11.50-12.00	Discussion
12.00-12.30	Plenary 18: Vaccine-induced immunity against SARS-CoV-2 on short and long-term – Gunilla Karlsson Hedestam, Sweden
12.30-12.40	Discussion
12.40	Lunch
13.40	Plenary Session IX - The immunology of Covid-19 and genetic aspects Moderators: Magnus Gisslén & Annika Karlsson
13.40-14.20	Plenary 19: Genetic risk factors for severe Covid-19 – Hugo Zeberg, Sweden
14.20-14.30	Discussion
14.30-15.00	Plenary 20: The immunology of Covid-19 – Alba Grifoni, United States
15.00-15.10	Discussion
15.10	Short break
15.20	Plenary Session X - Covid-19 in light of previous and future pandemics Moderators: Magnus Gottfredsson & Dag Henrik Reikvam
15.20-15.50	Plenary 21: How has the pandemic affected public health? – Anders Tegnell, Sweden
15.50-16.00	Discussion
16.00-16.30	Plenary 22: Bats, viruses and pandemics: are we ready for SARS3? – Linfa Wang, Singapore
16.30-16.40	Discussion
16.40	Concluding remarks